New kidney drug interaction study launches in healthy volunteers
NCT ID NCT07181265
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study tests how a new drug called JMKX003142 interacts with two common medications—amiodarone (for heart rhythm) and febuxostat (for gout)—in 48 healthy Chinese adults. Participants will take the drugs in sequence to measure how their bodies process them. The goal is to gather safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JMKX003142
- What this could lead to
- If successful, this study could help determine safe dosing of JMKX003142 when taken with other common drugs, supporting future trials for polycystic kidney disease.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. It only measures drug levels, not effectiveness. Results may not predict real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 48 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Able to participate and comply with all study procedures and restrictions, and willing to provide written informed consent to participate in the study. 2. Healthy adult males and/or females, 18 to 45 years of age (inclusive) at the date of signed consent form. Body mass index (BMI) greater than or equal to 18 and less than 32 (kg/m2) and a minimum body weight of 45 kg. 3. The health of the subjects was determined by the investigator based on medical history, physical examination, clinical laboratory examination, and 12-lead electrocardiogram, all of which were determined by the investigator to be normal or not clinically significant. 4. Women of child-bearing potential and sexually active males willing to use highly effective methods of contraception from screening until 3 months after last dose of study drug. In addition, participants must not donate sperm/egg for the time period specified above. Exclusion Criteria: 1. Subjects having hypersensitivity to study drug or have a history of allergies to multiple drugs, foods, or other substances 2. History or presence of significant circulatory system, respiratory system, digestive system, blood system, urinary and reproductive system, endocrine and metabolic system, nervous system, mental system, muscular and skeletal system, skin system, lymphatic system, immune system, Otolaryngology or other related systems disease or disorder. as well as systemic or local acute or chronic infections. 3. Subjects with dysphagia, gastrointestinal diseases, or any conditions that may affect drug absorption; such as a history of hepatobiliary and pancreatic diseases, gastrointestinal diseases, gastrointestinal surgery (except appendectomy), or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea. 4. Vital signs during the screening period meet any of the following conditions: systolic blood pressure \>140 mmHg or \<90 mmHg; diastolic blood pressure \>90 mmHg or \<50 mmHg (Cohort 1: diastolic blood pressure \>90 mmHg or \<60 mmHg); pulse \>100 beats/min or \<50 beats/min (Cohort 1: pulse \>100 beats/min or \<60 beats/min); ear temperature \>37.5°C or \<35°C. 5. History of QTc interval prolongation or abnormal ECG results during screening, QTcF ≥ 450 ms for males or ≥ 470 ms for females, or QRS interval \> 120 ms.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autosomal dominant polycystic kidney disease (adpkd) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will a kidney disease drug alter birth control?
- Can a Low-Carb diet calm kidney disease inflammation?
- Large study tracks kidney disease progression in thousands of patients
- New hope for dialysis patients: non-surgical kidney reduction could clear the way for transplant
- Could a drug for acromegaly protect kidneys in polycystic disease?
- Drug interaction study: VX-407 and oral contraceptives